Loading
First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.
Ghayas Issa led and was first author of the AUGMENT-101 phase 1 report in Nature showing the menin inhibitor revumenib produces remissions in heavily pretreated KMT2A-rearranged and NPM1-mutant acute leukaemia, and of the pivotal phase 2 analysis that led to its 2024 approval. He leads menin inhibitor combination trials and studies of resistance (MEN1 mutations) at MD Anderson.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin and the tags aml, menin.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia and the tags aml, targeted-therapy.
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin, Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, MD Anderson Cancer Center, Acute myeloid leukaemia and the tag aml.
Shares Revumenib, Acute myeloid leukaemia and the tag aml.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin.
Shares Revumenib, Menin, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/